% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Quandt:142110,
author = {J. Quandt$^*$ and C. Schlude$^*$ and M. Bartoschek$^*$ and
R. Will$^*$ and A. Cid-Arregui$^*$ and S. Schölch and C.
Reissfelder and J. Weitz and M. Schneider and S. Wiemann$^*$
and F. Momburg$^*$ and P. Beckhove$^*$},
title = {{L}ong-peptide vaccination with driver gene mutations in
p53 and {K}ras induces cancer mutation-specific effector as
well as regulatory {T} cell responses.},
journal = {OncoImmunology},
volume = {7},
number = {12},
issn = {2162-402X},
address = {Abingdon},
publisher = {Taylor $\&$ Franics},
reportid = {DKFZ-2018-02340},
pages = {e1500671 -},
year = {2018},
abstract = {Mutated proteins arising from somatic mutations in tumors
are promising targets for cancer immunotherapy. They
represent true tumor-specific antigens (TSAs) as they are
exclusively expressed in tumors, reduce the risk of
autoimmunity and are more likely to overcome tolerance
compared to wild-type (wt) sequences. Hence, we designed a
panel of long peptides (LPs, 28-35 aa) comprising driver
gene mutations in TP35 and KRAS frequently found in
gastrointestinal tumors to test their combined
immunotherapeutic potential. We found increased numbers of T
cells responsive against respective mutated and wt peptides
in colorectal cancer patients that carry the tested
mutations in their tumors than patients with other
mutations. Further, active immunization of
HLA(-A2/DR1)-humanized mice with mixes of the same mutated
LPs yielded simultaneous, polyvalent CD8+/CD4+ T cell
responses against the majority of peptides. Peptide-specific
T cells possessed a multifunctional cytokine profile with
CD4+ T cells showing a TH1-like phenotype. Two mutated
peptides (Kras[G12V], p53[R248W]) induced significantly
higher T cell responses than corresponding wt sequences and
comprised HLA-A2/DR1-restricted mutated epitopes. However,
vaccination with the same highly immunogenic LPs strongly
increased systemic regulatory T cells (Treg) numbers in a
syngeneic sarcoma model over-expressing these mutated
protein variants and resulted in accelerated tumor
outgrowth. In contrast, tumor outgrowth was delayed when
vaccination was directed against tumor-intrinsic Kras/Tp53
mutations of lower immunogenicity. Conclusively, we show
that LP vaccination targeting multiple mutated TSAs elicits
polyvalent, multifunctional, and mutation-specific effector
T cells capable of targeting tumors. However, the success of
this therapeutic approach can be hampered by
vaccination-induced, TSA-specific Tregs.},
cin = {D015 / B050 / W110 / D120 / D122},
ddc = {610},
cid = {I:(DE-He78)D015-20160331 / I:(DE-He78)B050-20160331 /
I:(DE-He78)W110-20160331 / I:(DE-He78)D120-20160331 /
I:(DE-He78)D122-20160331},
pnm = {314 - Tumor immunology (POF3-314)},
pid = {G:(DE-HGF)POF3-314},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30524892},
pmc = {pmc:PMC6279329},
doi = {10.1080/2162402X.2018.1500671},
url = {https://inrepo02.dkfz.de/record/142110},
}